US Patent 11254725 Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
Patent 11254725 was granted and assigned to Biomarin Pharmaceutical (company) on February, 2022 by the United States Patent and Trademark Office.
Currently, there are no issues on this topic.
Find more entities like US Patent 11254725 Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
